FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3170083312> ?p ?o ?g. }

• W3170083312 endingPage "e16065" @default.
• W3170083312 startingPage "e16065" @default.
• W3170083312 abstract "e16065 Background: The phase 2 part of the study hypothesizes HER-Vaxx (IMU-131) will provide treatment benefits consistent with traditional monoclonal antibodies that target HER2 in patients with confirmed Her2+ advanced or metastatic gastric cancer with a corresponding adaptive immune response without added toxicity. In the phase 1b dose finding part of the study tumor response of patients who received 50ug dose strongly correlated with antibody levels with 50ug selected as the phase 2 dose (Wiedermann et. al., 2019). Phase 2 is a randomized two arm study of either HER-Vaxx plus standard chemotherapy or standard chemotherapy alone. The primary endpoint is overall survival, with progression-free survival, safety and immune related changes in humoral and cellular immunogenicity secondary endpoints. Methods: Patients received SOC chemotherapy for a maximum of 6 cycles with the HER-Vaxx group also receiving 50ug dose of IMU-131 at Baseline/Day 0, Day 14, Day 35, Day 77 and then every 63 days until disease progression. The per protocol pre-planned first interim analysis (OS, PFS and safety) in a total of 27 patients after 15 progression events was reviewed by the independent data monitoring committee (IDMC). Results: Within ITT analysis, 8 of 27 patients died on the control arm and 4 on the HER-Vaxx plus SOC chemotherapy arm with an overall survival HR of 0.418 (2 sided 80% CI: 0.186, 0.942) and a 1-sided p-value of 0.083. Out of 27 patients, 9 patients progressed on the control arm while 6 patients progressed on the HER-Vaxx plus SOC chemotherapy arm with a HR of 0.532 (2 sided 80% CI: 0.267, 1.060) and a 1-sided p-value of 0.086. A robust HER2 specific antibody response developed in the HER-Vaxx arm compared to the control arm whereas there was no difference in safety between the two treatment arms. Conclusions: The IDMC confirmed that the safety of the study was favorable with no added toxicity of HER-Vaxx and SOC chemotherapy with a favorable risk-benefit for the combination. The study has completed enrollment and final data is expected in late 2021. Clinical trial information: NCT02795988." @default.
• W3170083312 created "2021-06-22" @default.
• W3170083312 creator A5004447476 @default.
• W3170083312 creator A5004575489 @default.
• W3170083312 creator A5005155042 @default.
• W3170083312 creator A5006427826 @default.
• W3170083312 creator A5015773183 @default.
• W3170083312 creator A5029096381 @default.
• W3170083312 creator A5032955590 @default.
• W3170083312 creator A5035852624 @default.
• W3170083312 creator A5036108163 @default.
• W3170083312 creator A5041880936 @default.
• W3170083312 creator A5047824506 @default.
• W3170083312 creator A5048367683 @default.
• W3170083312 creator A5068495326 @default.
• W3170083312 creator A5069732099 @default.
• W3170083312 creator A5069961709 @default.
• W3170083312 creator A5070079861 @default.
• W3170083312 date "2021-05-20" @default.
• W3170083312 modified "2023-09-27" @default.
• W3170083312 title "HERIZON: A phase 1B/2 open-label study of imu-131 HER2/neu peptide vaccine PLUS standard of care chemotherapy with randomization in phase 2 in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction." @default.
• W3170083312 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.e16065" @default.
• W3170083312 hasPublicationYear "2021" @default.
• W3170083312 type Work @default.
• W3170083312 sameAs 3170083312 @default.
• W3170083312 citedByCount "1" @default.
• W3170083312 countsByYear W31700833122022 @default.
• W3170083312 crossrefType "journal-article" @default.
• W3170083312 hasAuthorship W3170083312A5004447476 @default.
• W3170083312 hasAuthorship W3170083312A5004575489 @default.
• W3170083312 hasAuthorship W3170083312A5005155042 @default.
• W3170083312 hasAuthorship W3170083312A5006427826 @default.
• W3170083312 hasAuthorship W3170083312A5015773183 @default.
• W3170083312 hasAuthorship W3170083312A5029096381 @default.
• W3170083312 hasAuthorship W3170083312A5032955590 @default.
• W3170083312 hasAuthorship W3170083312A5035852624 @default.
• W3170083312 hasAuthorship W3170083312A5036108163 @default.
• W3170083312 hasAuthorship W3170083312A5041880936 @default.
• W3170083312 hasAuthorship W3170083312A5047824506 @default.
• W3170083312 hasAuthorship W3170083312A5048367683 @default.
• W3170083312 hasAuthorship W3170083312A5068495326 @default.
• W3170083312 hasAuthorship W3170083312A5069732099 @default.
• W3170083312 hasAuthorship W3170083312A5069961709 @default.
• W3170083312 hasAuthorship W3170083312A5070079861 @default.
• W3170083312 hasConcept C121608353 @default.
• W3170083312 hasConcept C126322002 @default.
• W3170083312 hasConcept C141071460 @default.
• W3170083312 hasConcept C143998085 @default.
• W3170083312 hasConcept C168563851 @default.
• W3170083312 hasConcept C203014093 @default.
• W3170083312 hasConcept C203092338 @default.
• W3170083312 hasConcept C2776694085 @default.
• W3170083312 hasConcept C2777909004 @default.
• W3170083312 hasConcept C2778336483 @default.
• W3170083312 hasConcept C2780739268 @default.
• W3170083312 hasConcept C2780868878 @default.
• W3170083312 hasConcept C31760486 @default.
• W3170083312 hasConcept C526805850 @default.
• W3170083312 hasConcept C61943457 @default.
• W3170083312 hasConcept C71924100 @default.
• W3170083312 hasConcept C8891405 @default.
• W3170083312 hasConcept C90924648 @default.
• W3170083312 hasConceptScore W3170083312C121608353 @default.
• W3170083312 hasConceptScore W3170083312C126322002 @default.
• W3170083312 hasConceptScore W3170083312C141071460 @default.
• W3170083312 hasConceptScore W3170083312C143998085 @default.
• W3170083312 hasConceptScore W3170083312C168563851 @default.
• W3170083312 hasConceptScore W3170083312C203014093 @default.
• W3170083312 hasConceptScore W3170083312C203092338 @default.
• W3170083312 hasConceptScore W3170083312C2776694085 @default.
• W3170083312 hasConceptScore W3170083312C2777909004 @default.
• W3170083312 hasConceptScore W3170083312C2778336483 @default.
• W3170083312 hasConceptScore W3170083312C2780739268 @default.
• W3170083312 hasConceptScore W3170083312C2780868878 @default.
• W3170083312 hasConceptScore W3170083312C31760486 @default.
• W3170083312 hasConceptScore W3170083312C526805850 @default.
• W3170083312 hasConceptScore W3170083312C61943457 @default.
• W3170083312 hasConceptScore W3170083312C71924100 @default.
• W3170083312 hasConceptScore W3170083312C8891405 @default.
• W3170083312 hasConceptScore W3170083312C90924648 @default.
• W3170083312 hasIssue "15_suppl" @default.
• W3170083312 hasLocation W31700833121 @default.
• W3170083312 hasOpenAccess W3170083312 @default.
• W3170083312 hasPrimaryLocation W31700833121 @default.
• W3170083312 hasRelatedWork W1999778859 @default.
• W3170083312 hasRelatedWork W2046104452 @default.
• W3170083312 hasRelatedWork W2261580129 @default.
• W3170083312 hasRelatedWork W2563490717 @default.
• W3170083312 hasRelatedWork W2589517324 @default.
• W3170083312 hasRelatedWork W2754118255 @default.
• W3170083312 hasRelatedWork W2799607207 @default.
• W3170083312 hasRelatedWork W3170083312 @default.
• W3170083312 hasRelatedWork W4248204656 @default.
• W3170083312 hasRelatedWork W4304690509 @default.
• W3170083312 hasVolume "39" @default.
• W3170083312 isParatext "false" @default.
• W3170083312 isRetracted "false" @default.
• W3170083312 magId "3170083312" @default.

• next